FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089761109> ?p ?o ?g. }

• W3089761109 endingPage "2311" @default.
• W3089761109 startingPage "2299" @default.
• W3089761109 abstract "Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers. Consistent basic data suggest that these same checkpoints are critical negative regulators of atherosclerosis. Therefore, our objectives were to test whether ICIs were associated with accelerated atherosclerosis and a higher risk of atherosclerosis-related cardiovascular events.The study was situated in a single academic medical center. The primary analysis evaluated whether exposure to an ICI was associated with atherosclerotic cardiovascular events in 2842 patients and 2842 controls matched by age, a history of cardiovascular events, and cancer type. In a second design, a case-crossover analysis was performed with an at-risk period defined as the 2-year period after and the control period as the 2-year period before treatment. The primary outcome was a composite of atherosclerotic cardiovascular events (myocardial infarction, coronary revascularization, and ischemic stroke). Secondary outcomes included the individual components of the primary outcome. In addition, in an imaging substudy (n=40), the rate of atherosclerotic plaque progression was compared from before to after the ICI was started. All study measures and outcomes were blindly adjudicated.In the matched cohort study, there was a 3-fold higher risk for cardiovascular events after starting an ICI (hazard ratio, 3.3 [95% CI, 2.0-5.5]; P<0.001). There was a similar increase in each of the individual components of the primary outcome. In the case-crossover, there was also an increase in cardiovascular events from 1.37 to 6.55 per 100 person-years at 2 years (adjusted hazard ratio, 4.8 [95% CI, 3.5-6.5]; P<0.001). In the imaging study, the rate of progression of total aortic plaque volume was >3-fold higher with ICIs (from 2.1%/y before 6.7%/y after). This association between ICI use and increased atherosclerotic plaque progression was attenuated with concomitant use of statins or corticosteroids.Cardiovascular events were higher after initiation of ICIs, potentially mediated by accelerated progression of atherosclerosis. Optimization of cardiovascular risk factors and increased awareness of cardiovascular risk before, during, and after treatment should be considered among patients on an ICI." @default.
• W3089761109 created "2020-10-08" @default.
• W3089761109 creator A5005428936 @default.
• W3089761109 creator A5008479799 @default.
• W3089761109 creator A5017972924 @default.
• W3089761109 creator A5022162371 @default.
• W3089761109 creator A5024590816 @default.
• W3089761109 creator A5032297344 @default.
• W3089761109 creator A5034105954 @default.
• W3089761109 creator A5035343389 @default.
• W3089761109 creator A5037380702 @default.
• W3089761109 creator A5048185686 @default.
• W3089761109 creator A5055724348 @default.
• W3089761109 creator A5058331751 @default.
• W3089761109 creator A5065587860 @default.
• W3089761109 creator A5068710430 @default.
• W3089761109 creator A5069837934 @default.
• W3089761109 creator A5076038933 @default.
• W3089761109 creator A5077995279 @default.
• W3089761109 creator A5084378579 @default.
• W3089761109 creator A5087164932 @default.
• W3089761109 creator A5090606294 @default.
• W3089761109 date "2020-12-15" @default.
• W3089761109 modified "2023-10-16" @default.
• W3089761109 title "Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque" @default.
• W3089761109 cites W2003188915 @default.
• W3089761109 cites W2031635700 @default.
• W3089761109 cites W2067640722 @default.
• W3089761109 cites W2067687558 @default.
• W3089761109 cites W2081716782 @default.
• W3089761109 cites W2094316018 @default.
• W3089761109 cites W2108231461 @default.
• W3089761109 cites W2120179549 @default.
• W3089761109 cites W2121405879 @default.
• W3089761109 cites W2121878069 @default.
• W3089761109 cites W2127933204 @default.
• W3089761109 cites W2139585854 @default.
• W3089761109 cites W2141259519 @default.
• W3089761109 cites W2144873061 @default.
• W3089761109 cites W2160133249 @default.
• W3089761109 cites W2166910397 @default.
• W3089761109 cites W2298991506 @default.
• W3089761109 cites W2317660163 @default.
• W3089761109 cites W2346445964 @default.
• W3089761109 cites W2547133566 @default.
• W3089761109 cites W2592187743 @default.
• W3089761109 cites W2753065806 @default.
• W3089761109 cites W2753432434 @default.
• W3089761109 cites W2766940177 @default.
• W3089761109 cites W2774533844 @default.
• W3089761109 cites W2785715721 @default.
• W3089761109 cites W2789315292 @default.
• W3089761109 cites W2791483720 @default.
• W3089761109 cites W2792588444 @default.
• W3089761109 cites W2793167197 @default.
• W3089761109 cites W2797309423 @default.
• W3089761109 cites W2797675588 @default.
• W3089761109 cites W2798160602 @default.
• W3089761109 cites W2803500132 @default.
• W3089761109 cites W2877328171 @default.
• W3089761109 cites W2888880602 @default.
• W3089761109 cites W2891761236 @default.
• W3089761109 cites W2900354984 @default.
• W3089761109 cites W2929415048 @default.
• W3089761109 cites W2940759533 @default.
• W3089761109 cites W2943781197 @default.
• W3089761109 cites W2955729565 @default.
• W3089761109 cites W2972338824 @default.
• W3089761109 cites W2979167769 @default.
• W3089761109 cites W2995355574 @default.
• W3089761109 cites W2997277554 @default.
• W3089761109 cites W2998549695 @default.
• W3089761109 cites W3003308809 @default.
• W3089761109 cites W3007666278 @default.
• W3089761109 cites W3034894621 @default.
• W3089761109 doi "https://doi.org/10.1161/circulationaha.120.049981" @default.
• W3089761109 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7736526" @default.
• W3089761109 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33003973" @default.
• W3089761109 hasPublicationYear "2020" @default.
• W3089761109 type Work @default.
• W3089761109 sameAs 3089761109 @default.
• W3089761109 citedByCount "226" @default.
• W3089761109 countsByYear W30897611092020 @default.
• W3089761109 countsByYear W30897611092021 @default.
• W3089761109 countsByYear W30897611092022 @default.
• W3089761109 countsByYear W30897611092023 @default.
• W3089761109 crossrefType "journal-article" @default.
• W3089761109 hasAuthorship W3089761109A5005428936 @default.
• W3089761109 hasAuthorship W3089761109A5008479799 @default.
• W3089761109 hasAuthorship W3089761109A5017972924 @default.
• W3089761109 hasAuthorship W3089761109A5022162371 @default.
• W3089761109 hasAuthorship W3089761109A5024590816 @default.
• W3089761109 hasAuthorship W3089761109A5032297344 @default.
• W3089761109 hasAuthorship W3089761109A5034105954 @default.
• W3089761109 hasAuthorship W3089761109A5035343389 @default.
• W3089761109 hasAuthorship W3089761109A5037380702 @default.
• W3089761109 hasAuthorship W3089761109A5048185686 @default.
• W3089761109 hasAuthorship W3089761109A5055724348 @default.

• next